Last updated: August 06, 2026

Application No. 18/258,203

FAP BINDING MOLECULES AND USES THEREOF

Non-Final OA

Filed

Jun 16, 2023

Priority

Dec 18, 2020 — provisional 63/127,885 +2 more

Examiner

HADDAD, MAHER M

Art Unit

1641

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Bioardis LLC

OA Round

1 (Non-Final)

This examiner grants 50% of cases after interview

— +53.9% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 1053 resolved cases, 2023–2026

Examiner Intelligence

HADDAD, MAHER M View full profile →

Grants 50% of resolved cases

Career Allowance Rate

532 granted / 1053 resolved

-9.5% vs TC avg

Strong +54% interview lift

Without

With

+53.9%

Interview Lift

resolved cases with interview

Typical timeline

3y 0m

Avg Prosecution

58 currently pending

Career history

1112

Total Applications

across all art units

Statute-Specific Performance

§101

2.7%

-37.3% vs TC avg

§103

29.1%

-10.9% vs TC avg

§102

18.4%

-21.6% vs TC avg

§112

33.6%

-6.4% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1053 resolved cases

Prosecution Timeline

Jun 16, 2023

Application Filed

Jul 31, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/250,440

Patent 12698327

ANTI-TIGIT ANTIBODY, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

3y 3m to grant Granted Aug 04, 2026

17/923,317

Patent 12692320

BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20

3y 8m to grant Granted Jul 28, 2026

18/009,849

Patent 12692303

ANTI-HUMAN INTERLEUKIN 23 MONOCLONAL ANTIBODY AND APPLICATION THEREOF

3y 7m to grant Granted Jul 28, 2026

18/340,797

Patent 12686713

METHODS FOR TREATING COMPLEMENT-MEDIATED DISEASES

3y 0m to grant Granted Jul 21, 2026

17/614,288

Patent 12679885

COMPOSITION AND METHODS TO TREAT ECTODERMAL DYSPLASIA 2, CLOUSTON TYPE

1y 0m to grant Granted Jul 14, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

50%

Grant Probability

99%

With Interview (+53.9%)

3y 0m (~0m remaining)

Median Time to Grant

Low

PTA Risk

Based on 1053 resolved cases by this examiner. Grant probability derived from career allowance rate.